Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target lifted by analysts at HSBC from $800.00 to $920.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HSBC’s price objective would suggest a potential upside of 14.78% from the stock’s previous close.
Several other equities research analysts have also issued reports on REGN. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Canaccord Genuity Group reduced their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Citigroup upped their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Finally, Leerink Partners lifted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research report on Monday, August 17th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $802.18.
Read Our Latest Report on REGN
Regeneron Pharmaceuticals Price Performance
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter last year, the business posted $12.81 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.
Insider Activity at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, Director Arthur Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 4,146 shares of company stock worth $3,432,488. Company insiders own 6.97% of the company’s stock.
Hedge Funds Weigh In On Regeneron Pharmaceuticals
Large investors have recently added to or reduced their stakes in the company. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $26,000. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Finally, Birchwood Financial Partners Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.
Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- This Corner of the Market Is Outperforming the Benchmark—And It’s Not AI
- Victoria’s Secret’s Comeback Is Real—The Stock’s Problem Is Different
- Apple Unveils Foldable iPhone, But Stock’s Muted Reaction Raises Questions
- Palantir’s New U.S. Army Contract Brings It Closer to Owning the Full Battlefield System
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
